Skip Ribbon Commands
Skip to main content
frontpage
 
Pharma Industry Finland  
Strategic aim of PIF
  • Safeguard the operating conditions of the pharmaceutical companies in Finland
  • Make new medicines available to patients without delay and maintain an extensive choice of medicines in their use
  • Ensure sufficient competition and competitive neutrality on the pharmaceutical market
  • Offer reliable information to support decision-making
  • Have courage to raise and discuss difficult issues
  • Have an open perspective on overall healthcare expenses, also as concerns pharmaceutical expenditure
 
17/04/2013
Wholesale prices of medicines reimbursed by KELA decreased in 2012
Medicines wholesale prices continued to decline in 2012, following the trend prevailing throughout the 2000s. According to the index published by Statistics Finland, medicines wholesale prices were down 1.1 per cent in 2012 whereas the general price level was up 2.8 per cent during the same period. The decrease was particularly marked in reimbursable medicines. In pharmaceutical contexts, 'wholesale price' refers to the share accounted for by the pharmaceutical company and wholesaler in the medicine retail price.

16/01/2013
The reimbursement system took a step to the right direction - more was offered
According to Pharma Industry Finland PIF, the working group for the reform of the medicines reimbursement system had some good proposals in their report recently handed over to Minister Paula Risikko. However, there was potential for more. The reimbursement system took a step to the right direction as the initial patient co-payment and the decrease in the medicines expense ceiling target the support at those who need many medicines. However, the proposal falls short of the objectives because it does not help to keep up the Finnish healthcare system with the international progress. The further development work proposed by the working group must be launched rapidly, implementing it in collaboration with the pharmaceutical branch operators.

07/01/2013
Medical research to underpin Finland's future growth
Jussi Merikallio, General Manager of Pharma Industry Finland PIF, finds that medical research - and pharmaceutical research as its integral part – can constitute an important footing for Finland’s future growth. Published on 21 November 2012, PIF's survey crystallises six factors to unleash the growth potential of pharmaceutical research in Finland.

 
 
Supervisory Commission of Medicinal Products  

The Supervisory Commission for the Marketing of Medicinal Products guides and monitors the compliance with the Code.

The Code of Ethics is on this page.

 
Pharmaceutical Information Centre  
Pharmaceutical Information Centre: expert in providing pharmaceutical information to healthcare professionals and consumers.